265 related articles for article (PubMed ID: 33693908)
1. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
Gruber LM; Jasim S; Ducharme-Smith A; Weingarten T; Young WF; Bancos I
J Clin Endocrinol Metab; 2021 May; 106(6):e2393-e2401. PubMed ID: 33693908
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
Naruse M; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Harada T; Kawata N; Takekoshi K
Endocr J; 2018 Mar; 65(3):359-371. PubMed ID: 29353821
[TBL] [Abstract][Full Text] [Related]
3. Correlation between urinary fractionated metanephrines in 24-hour and spot urine samples for evaluating the therapeutic effect of metyrosine: a subanalysis of a multicenter, open-label phase I/II study.
Takekoshi K; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Asada S; Kawata N; Naruse M
Endocr J; 2019 Dec; 66(12):1063-1072. PubMed ID: 31511435
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
Niemeijer ND; Alblas G; van Hulsteijn LT; Dekkers OM; Corssmit EP
Clin Endocrinol (Oxf); 2014 Nov; 81(5):642-51. PubMed ID: 25041164
[TBL] [Abstract][Full Text] [Related]
5. Surgical management of pheochromocytoma with the use of metyrosine.
Perry RR; Keiser HR; Norton JA; Wall RT; Robertson CN; Travis W; Pass HI; Walther MM; Linehan WM
Ann Surg; 1990 Nov; 212(5):621-8. PubMed ID: 1978640
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Metyrosine Improves Cardiovascular Outcomes for Patients Undergoing Surgery for Pheochromocytoma and Paraganglioma.
Wachtel H; Kennedy EH; Zaheer S; Bartlett EK; Fishbein L; Roses RE; Fraker DL; Cohen DL
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S646-54. PubMed ID: 26374407
[TBL] [Abstract][Full Text] [Related]
7. The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas.
Ohmachi Y; Yamamoto M; Inaba Y; Makino S; Urai S; Matsumoto R; Bando H; Kanie K; Tsujimoto Y; Motomura Y; Sasaki Y; Oi-Yo Y; Yamamoto N; Suzuki M; Takahashi M; Iguchi G; Kanzawa M; Furukawa J; Shigemura K; Mizobuchi S; Ogawa W; Fukuoka H
Endocrine; 2024 May; 84(2):694-703. PubMed ID: 38206436
[TBL] [Abstract][Full Text] [Related]
8. Metyrosine and pheochromocytoma.
Steinsapir J; Carr AA; Prisant LM; Bransome ED
Arch Intern Med; 1997 Apr; 157(8):901-6. PubMed ID: 9129550
[TBL] [Abstract][Full Text] [Related]
9. Preoperative Management of Pheochromocytoma and Paraganglioma.
Fang F; Ding L; He Q; Liu M
Front Endocrinol (Lausanne); 2020; 11():586795. PubMed ID: 33117294
[TBL] [Abstract][Full Text] [Related]
10. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
Gagnon N; Mansour S; Bitton Y; Bourdeau I
Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
[TBL] [Abstract][Full Text] [Related]
11. Approach to the Patient: Perioperative Management of the Patient with Pheochromocytoma or Sympathetic Paraganglioma.
Berends AMA; Kerstens MN; Lenders JWM; Timmers HJLM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32726444
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Cardiac Complications in Patients With Pheochromocytoma and Paraganglioma: A Retrospective Single-Center Study.
Zhao L; Meng X; Mei Q; Fan H; Liu Y; Zhou X; Zhu H; Zhang S
Front Endocrinol (Lausanne); 2022; 13():877341. PubMed ID: 35721724
[TBL] [Abstract][Full Text] [Related]
13. Rates of Pheochromocytoma/Paraganglioma Screening in At-Risk Populations.
Grigoryan S; Nhan W; Zhang L; Urban C; Zhao L; Turcu AF
J Clin Endocrinol Metab; 2023 May; 108(6):e343-e349. PubMed ID: 36469797
[TBL] [Abstract][Full Text] [Related]
14. Failure of metyrosine therapy for preoperative management of pheochromocytoma: a case report.
Thanapaalasingham K; Pollmann AS; Schelew B
Can J Anaesth; 2015 Dec; 62(12):1303-7. PubMed ID: 26362800
[TBL] [Abstract][Full Text] [Related]
15. Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature.
Bancos I; Atkinson E; Eng C; Young WF; Neumann HPH;
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):13-21. PubMed ID: 33248478
[TBL] [Abstract][Full Text] [Related]
16. Seizures in patients with a phaeochromocytoma/paraganglioma (PPGL): A review of clinical cases and postulated pathological mechanisms.
Li Y; Zhang B
Rev Neurol (Paris); 2019 Oct; 175(9):495-505. PubMed ID: 31133278
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma.
Tanabe A; Naruse M; Nomura K; Tsuiki M; Tsumagari A; Ichihara A
Horm Cancer; 2013 Apr; 4(2):103-10. PubMed ID: 23361939
[TBL] [Abstract][Full Text] [Related]
18. Perioperative hemodynamics and outcomes of patients on metyrosine undergoing resection of pheochromocytoma or paraganglioma.
Butz JJ; Weingarten TN; Cavalcante AN; Bancos I; Young WF; McKenzie TJ; Schroeder DR; Martin DP; Sprung J
Int J Surg; 2017 Oct; 46():1-6. PubMed ID: 28803996
[TBL] [Abstract][Full Text] [Related]
19. Influence of duration of preoperative treatment with phenoxybenzamine and secretory phenotypes on perioperative hemodynamics and postoperative outcomes in pheochromocytoma and paraganglioma.
Yao Y; Guo Y; Fan J; Lin T; Wang L; Zhang S
Front Endocrinol (Lausanne); 2023; 14():1139015. PubMed ID: 37152936
[TBL] [Abstract][Full Text] [Related]
20. Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma.
Matsuo Y; Ashida K; Nagayama A; Moritaka K; Gobaru M; Yasuda J; Ogasawara N; Kurose H; Chikui K; Iwata S; Inoguchi Y; Hasuzawa N; Motomura S; Igawa T; Nomura M
Endocr Oncol; 2023 Jan; 3(1):e230006. PubMed ID: 37822367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
